SynOx is advancing emactuzumab, a best-in-class CSF-1R antibody for the treatment of tenosynovial giant cell tumors (TGCT) and other macrophage-driven diseases. The company is led by an experienced team with a track record of developing successful oncology therapeutics.
Location: Dublin, Ireland
Board director: Tom Heyman
Website: